Alterity Therapeutics Ltd. has announced the publication of a novel MRI endpoint from the bioMUSE Natural History Study in the peer-reviewed journal Annals of Clinical and Translational Neurology. The study introduces the MSA Atrophy Index (MSA-AI), a new neuroimaging measure developed to diagnose and track disease progression in Multiple System Atrophy $(MSA)$. Utilizing advanced MRI technology, the research demonstrated that statistically significant reductions in brain volume over 12 months correlated with clinical worsening of MSA. The study captured a broad spectrum of clinical severity and atrophy patterns, effectively distinguishing MSA from related synucleinopathies. The results of this study have been presented and are available in the publication entitled "The MSA Atrophy Index (MSA-AI): An Imaging Marker for Diagnosis and Clinical Progression in Multiple System Atrophy."